4.3 Article

Endoplasmic reticulum stress, unfolded protein response and development of colon adenocarcinoma

期刊

VIRCHOWS ARCHIV
卷 469, 期 2, 页码 145-154

出版社

SPRINGER
DOI: 10.1007/s00428-016-1961-6

关键词

Endoplasmic reticulum stress; Unfolded protein response; Colon adenocarcinoma; Colon premalignancy; Tissue microarray

资金

  1. Societe Francaise de Pathologie

向作者/读者索取更多资源

When misfolded proteins accumulate in the endoplasmic reticulum (ER), the cell is said to experience ER stress. This triggers an unfolded protein response (UPR) to restore the balance between misfolded proteins and ER chaperones such as BiP. UPR signalling is required for the growth of many solid cancers. In chronic ER stress, factors including CHOP have been shown to mediate cell death. Colorectal adenocarcinoma arises due to progressive changes within pre-malignant lesions. Our aim was to test the hypothesis that the expression of BiP and CHOP correlates with the progression of those pre-malignant lesions. Eighty-one patients with colon neoplasms treated at Rouen University Hospital between January 1, 2003 and January 1, 2013 were randomly selected. The expression of BiP and CHOP was estimated by immunohistochemical staining of a tissue microarray generated from colon cores: normal tissue, low-grade and high-grade adenoma, invasive colon adenocarcinoma and lymph node metastasis of colon adenocarcinoma. In parallel, nine cases comprising areas from normal epithelium to dyplasia to invasive carcinoma and included in the TMA were analysed on whole sections. As colon epithelium shows increasing evidence of pre-malignant and then malignant changes, BiP expression significantly increases (p for trend < 0.001), whereas CHOP expression is attenuated (p for trend < 0.001). We identified a positive relationship between BiP expression and colon carcinogenesis, and a negative correlation for CHOP expression. These findings are consistent with a model in which ER stress accompanies oncogenesis and in which loss of proteins that mediate the toxicity of ER stress, such as CHOP, may facilitate tumorigenesis. This raises the exciting possibility that restoration of the negative feedback loop of UPR, if achievable, might antagonise the malignant process.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Mathematical & Computational Biology

Developing a predictive signature for two trial endpoints using the cross-validated risk scores method

Svetlana Cherlin, James M. S. Wason

Summary: The CVRS2 design is a new approach to develop and test the effectiveness of treatment in high-dimensional data. It considers the tradeoff between two outcomes and divides patients into clusters using bivariate risk scores. Through simulated data and a real clinical trial, we demonstrate the reliability and applicability of the CVRS2 design.

BIOSTATISTICS (2023)

Article Biology

Bayesian sample size determination using commensurate priors to leverage preexperimental data

Haiyan Zheng, Thomas Jaki, James M. S. Wason

Summary: This paper develops Bayesian sample size formulae that can incorporate preexperimental information from multiple sources to support both the design and analysis of experiments comparing two groups. The methodology can be applied to various scenarios and provides exact solutions or a search procedure for sample size determination.

BIOMETRICS (2023)

Article Health Care Sciences & Services

Point estimation following a two-stage group sequential trial

Michael J. Grayling, James M. S. Wason

Summary: This article describes nine possible point estimators within a common general framework for a two-stage group sequential trial, and compares their performance in five example trial settings. The study finds that two mean adjusted estimators perform best in terms of marginal residual mean square error, considering both conditional and marginal biases.

STATISTICAL METHODS IN MEDICAL RESEARCH (2023)

Article Mathematical & Computational Biology

Online error rate control for platform trials

David S. Robertson, James M. S. Wason, Franz Koenig, Martin Posch, Thomas Jaki

Summary: Platform trials evaluate multiple experimental treatments under a single master protocol, with the potential risk of inflating the overall type I error rate due to multiple treatment comparisons and non-pre-specified, time-dependent hypotheses. Online error rate control provides a solution to the problem of multiplicity for platform trials, testing each hypothesis one-by-one over time without knowledge of future tests.

STATISTICS IN MEDICINE (2023)

Article Medicine, Research & Experimental

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

Mark E. McClure, Seerapani Gopaluni, James Wason, Robert B. Henderson, Andre Van Maurik, Caroline C. O. Savage, Charles D. Pusey, Alan D. Salama, Paul A. Lyons, Jacinta Lee, Kim Mynard, David R. Jayne, Rachel B. Jones

Summary: The COMBIVAS study aims to evaluate the mechanistic effects of sequential therapy of belimumab and rituximab in patients with active PR3 AAV. The study includes 30 patients and lasts for 2 years, with a 12-month treatment period followed by a 12-month follow-up period. The primary endpoint is time to PR3 ANCA negativity.

TRIALS (2023)

Article Oncology

Assessment of endobronchial ultrasound-guided bronchoscopy (EBUS) intranodal forceps biopsy added to EBUS 19-gauge transbronchial needle aspiration: A blinded pathology panel analysis

Samy Lachkar, Quentin Faur, Florent Marguet, Liana Veresezan, Michael Bubenheim, Mathieu Salaun, Luc Thiberville, Jean-Christophe Sabourin, Florian Guisier, Nicolas Piton

Summary: This study aimed to assess the improvement in diagnostic yield with the combination of EBUS-TBNA and EBUS-IFB compared to EBUS-TBNA alone. The results showed that the diagnostic yield was 94% when EBUS-IFB was combined with EBUS-TBNA, compared to 77% with EBUS-TBNA alone. In terms of histology, the diagnostic yield for nonmalignant conditions was 92% with the combination, compared to 69% with EBUS-TBNA alone.

THORACIC CANCER (2023)

Article Medicine, General & Internal

Four 2x2 factorial trials of smartphone CBT to reduce subthreshold depression and to prevent new depressive episodes among adults in the community-RESiLIENT trial (Resilience Enhancement with Smartphone in LIving ENvironmenTs): a master protocol

Toshi A. Furukawa, Aran Tajika, Masatsugu Sakata, Yan Luo, Rie Toyomoto, Masaru Horikoshi, Tatsuo Akechi, Norito Kawakami, Takeo Nakayama, Naoki Kondo, Shingo Fukuma, Hisashi Noma, Helen Christensen, Ronald C. Kessler, Pim Cuijpers, James M. S. Wason

Summary: This study aims to develop an iCBT platform that can adapt to the evolving internet technologies and examine the short-term and long-term efficacy of different CBT skills for depression. The study will recruit 3520 participants with subthreshold depression and approximately 1700 participants without subthreshold depression to evaluate the short-term efficacy for reducing depressive symptoms and the long-term efficacy for preventing depression in the total sample.

BMJ OPEN (2023)

Article Mathematical & Computational Biology

A Comparison of Randomization Methods for Multi-Arm Clinical Trials

Ruqayya A. Azher, James M. S. Wason, Michael J. Grayling

Summary: Randomized controlled trials are the best design for evaluating treatment efficacy, and different randomization procedures can be used to achieve desirable properties. This study compares several allocation procedures for multi-arm trials and finds that stratified block randomization and the stratified block urn design consistently outperform other methods.

STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2023)

Article Medicine, General & Internal

Current practices in studies applying the target trial emulation framework: a protocol for a systematic review

Theophile Bigirumurame, Shaun Kuan Wei Hiu, M. Dawn Teare, James M. S. Wason, Andrew Bryant, Matthew Breckons

Summary: This systematic review aims to investigate the practices of studies that apply the target trial emulation framework to evaluate intervention effectiveness using existing observational data. The review will search multiple databases for relevant study reports and protocols and will use a narrative approach to synthesize and report the findings.

BMJ OPEN (2023)

Article Medicine, General & Internal

Dual bronchodilators in Bronchiectasis study (DIBS): protocol for a pragmatic, multicentre, placebo-controlled, three-arm, double-blinded, randomised controlled trial studying bronchodilators in preventing exacerbations of bronchiectasis

Miranda Morton, Nina Wilson, Tara Marie Homer, Laura Simms, Alison Steel, Rebecca Maier, James Wason, Laura Ternent, Alaa Abouhajar, Maria Allen, Richard Joyce, Victoria Hildreth, Rachel Lakey, Svetlana Cherlin, Adam Walker, Graham Devereux, James D. Chalmers, Adam T. Hill, Charles Haworth, John R. Hurst, Anthony De Soyza

Summary: This trial aims to investigate whether inhaled dual bronchodilators can reduce the number of exacerbations in bronchiectasis patients. It is a multicentre, double-blind, randomised controlled trial involving 600 adult patients with confirmed bronchiectasis. The primary outcome is the number of exacerbations requiring antibiotic treatment during a 12-month period.

BMJ OPEN (2023)

Review Oncology

Beyond the Frontline: A Triple-Line Approach of Thoracic Surgeons in Lung Cancer Management-State of the Art

Benjamin Bottet, Nicolas Piton, Jean Selim, Matthieu Sarsam, Florian Guisier, Jean-Marc Baste

Summary: Lung cancer is a heterogeneous disease that presents significant challenges in diagnosis and treatment. Recent advances in surgery, perioperative management, and targeted therapy have revolutionized the treatment landscape for this disease, offering new hope for patients. This review aims to provide a comprehensive understanding of the latest surgical approaches in lung cancer and emphasizes the importance of integrating these modalities within a patient-centered and personalized treatment pathway.

CANCERS (2023)

暂无数据